The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC).
 
Caicun Zhou
No Relationships to Disclose
 
Shengxiang Ren
No Relationships to Disclose
 
Yongzhong Luo
No Relationships to Disclose
 
Lei Wang
No Relationships to Disclose
 
Anwen Xiong
No Relationships to Disclose
 
Chunxia Su
No Relationships to Disclose
 
Zhihong Zhang
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Jin Zhou
No Relationships to Disclose
 
Xinmin Yu
Research Funding - BeiGene; BMS; Hansoh; Innovent Biologics; MSD
 
Yanping Hu
No Relationships to Disclose
 
Xiaodong Zhang
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Xiaoming Hou
No Relationships to Disclose
 
Yuanrong Dai
No Relationships to Disclose
 
Weifeng Song
No Relationships to Disclose
 
Baiyong Li
No Relationships to Disclose
 
Zhongmin Maxwell Wang
No Relationships to Disclose
 
Yu Xia
No Relationships to Disclose